Emerging Company Profile: Kallyope is translating early research of the gut-brain axis into small molecules that could have potential in a wide range of therapy areas. The company closed an $87m Series B funding round last year.
Kallyope Inc..'s early discovery research into the gut-brain axis is beginning to mature, with the company's focus now on translating that research into the development of potential drug candidates.
"I'm hopeful that no later than next year we will be in preclinical development and moving towards the clinic," CEO...
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
